Study in Patients With Asthma

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control drug.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dey
• Treatments: Formoterol Fumarate

Criteria

Inclusion Criteria:

-Require regular use of an inhaled Beta-2-selective adrenergic agent

Exclusion Criteria:

• Active acute or chronic disorders of the respiratory system within one month prior to screening

• Smoking history within the past 12 months or greater than a lifetime 10 pack-year smoking history

• Recent surgical interventions such as lung lobectomy or resection (< one year), or cardiothoracic interventions

• Life-threatening systemic and debilitating diseases.